Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

3rd Pharma Meets AI Conference 2027

3rd Pharma Meets AI Conference on 19 and 20 April 2027 in Barcelona, hosted by UBIQ Events. Director-level executives from leading pharmaceutical companies share their expertise and real-world case studies on how artificial intelligence is...

World Congress of Bronchology and Interventional Pulmonology 2026

We are excited to announce that the World Congress of Bronchology and Interventional Pulmonology 2026 will be hosted by the Thoracic Society of Australia and New Zealand in the vibrant city of Melbourne, Australia. We are excited to announce that...

3rd Global Summit on Heart and Cardiovascular Care 2026

3rd Global Summit on Heart and Cardiovascular Care” (Heart Congress 2026), taking place on November 26–27, 2026, in Barcelona, Spain as a HYBRID EVENT—offering participants the flexibility to join in person or virtually from anywhere across the...

VietPharma&Tech 2026

Vietnam Medical Devices Association highly appreciates Vietnam Advertisement and Fair Exhibition Joint Stock Company (VIETFAIR) organizing The international exhibition on Pharmaceutical Manufacturing Technology - VietPharmaTech 2026 / The...

SHARx’s Paul Pruitt Warns That Patent Expiration Does Not Guarantee Immediate Savings

A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market. Employers cannot control when a patent expires, a lawsuit is resolved, or when a biosimilar reaches the...

Seawolf Therapeutics Launches With $100 Million to Advance DNA-Based Therapies

Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform. Founding investor Versant Ventures led the seed round, followed by the...

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data at ASH 2026, Demonstrating Promising Leukemia Treatment Results

Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, highlighted preclinical findings from an abstract accepted for poster presentation at...

Bruker Announces the Appointment of Institute Director, Biopharma Entrepreneur, and Immunology Leader Dr. Eicke Latz to Its Board of Directors

Bruker Corporation announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist,...

CS Analytical to Offer Testing Services for Sunscreen Ingredients Used in Pharmaceutical and Cosmetic Products

CS Analytical (CSA), doing business as Raw Material Analytical (RMA), a cGMP laboratory dedicated to advancing product quality and patient safety, today announced that it is set to offer analytical testing for sunscreen ingredients used in...

6th International Conference on Cardiology 2026

6th International Conference on Cardiology. Held in the vibrant city of Bangkok, Thailand, this prestigious event will take place on November 13–14, 2026. 6th International Conference on Cardiology. Held in the vibrant city of Bangkok, Thailand,...

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

VectorY Therapeutics (“VectorY”), a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, today announced €74.5 million ($83.5 million) in new financing to advance its clinical and...

ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

ProBio, a global contract research, development, and manufacturing organization announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST,...

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and...

Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke...

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, announced its telehealth prescribing program. This program connects eligible...

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint...

Avanzanite Announces an Exclusive Agreement to License and Market Zemcelpro® in Europe

Avanzanite Bioscience B.V. a European pharmaceutical company focused on rare diseases, announced the conclusion of an exclusive licensing agreement with Montreal-based company Cordex Biologics, an ExCellThera Group company (“ExCellThera”), a...

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the...

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

Eli Lilly and Company announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will...

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel...